Drug Search Results

Selitrectinib

Alternative Names: selitrectinib, loxo-195, loxo195, loxo 195
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

For Solid Tumors Harboring NTRK Fusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03215511)

Mechanisms of Action: TRK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Selitrectinib

Countries in Clinic: Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Singapore, Spain, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2017-004246-20	P1	Completed	Oncology Unspecified	2023-06-21
LOXO-EXT-17005	P1	Completed	Oncology Solid Tumor Unspecified	2022-04-11

Recent News Events

Date	Type	Title
05/01/2024	PubMed	A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas.
02/01/2024	PubMed	Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
12/07/2023	PubMed	Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases.
07/26/2023	News Article	Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development
08/18/2022	News Article	AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene
12/06/2021	News Article	Global TRK Inhibitors Market, Drug Sales & Clinical Trials, & Dosage Insights Report 2021-2026 - ResearchAndMarkets.com
10/08/2021	News Article	Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions